Abstract and Introduction
Whether percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) improves clinical outcomes in patients with chronic coronary syndromes (CCS) has been a continuing area of investigation for more than two decades. While myocardial revascularization, principally with PCI, has been the standard of care for patients with acute coronary syndromes because it improves survival and reduces recurrent myocardial infarction (MI),[1,2] its role in patients with CCS is less clear.[2,3] Although several randomized clinical trials (RCTs) and meta-analyses indicate that OMT with PCI more effectively relieves angina, decreases the use of anti-anginal medications, and improves functional status and quality of life compared to OMT alone, none of these trials have demonstrated convincingly that an initial strategy of OMT + PCI improves 'hard' outcomes, including all-cause and cardiovascular mortality and MI during long-term follow-up.4–12 The recently reported results of the ISCHEMIA trial,[13,14] the largest prospective trial of OMT with or without myocardial revascularization, provide unique insight concerning the incremental benefit of revascularization in chronic coronary artery disease (CAD) patients with moderate-to-severe ischaemia and inform the selection of optimal management strategy.
Eur Heart J. 2021;42(14) © 2021 Oxford University Press
Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.